Table IV.
Cox multivariate analysis of OS and clinical characteristics among 72 patients with advanced non-small cell lung cancer carrying EGFR mutation.
| Clinical characteristics | Exp (B) | 95%CI | P-value |
|---|---|---|---|
| Sex | 0.018 | ||
| Male vs. female | 3.152 | 1.220–8.141 | |
| Age (year) | 0.411 | ||
| <70 vs. ≥70 | 1.455 | 0.595–3.559 | |
| Histological type | 0.009 | ||
| Adenocacinoma vs. squamous | 0.059 | 0.007–0.494 | |
| Clinical stage | 0.764 | ||
| IIIB vs. IV | 0.875 | 0.366–2.094 | |
| PS score | 0.368 | ||
| 0 or 1 vs. 2 | 0.646 | 0.250–1.671 | |
| Smoking history | 0.003 | ||
| Smoker vs. non-smoker | 8.322 | 2.061–33.614 | |
| EGFR-TKI | 0.787 | ||
| Gefitinib vs. erlotinib | 1.072 | 0.649–1.771 | |
| Group | 0.426 | ||
| Exon 19 deletions vs. an exon 21 mutation | 1.388 | 0.618–3.117 |
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; PS, performance status; OS, overall survival; CI, confidence interval; Exp (B), exponentiation of the B coefficient, an odds ratio.